- Home
- NRG vs RPRX Comparison
NRG vs RPRX Comparison
Compare NRG & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRG | RPRX |
|---|---|---|
| Founded | 1989 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.3B | 22.0B |
| IPO Year | 1997 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NRG | RPRX |
|---|---|---|
| Price | $132.19 | $54.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 5 |
| Target Price | ★ $203.00 | $51.40 |
| AVG Volume (30 Days) | 2.3M | ★ 3.3M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | 1.27% | ★ 1.90% |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.52 | ★ 0.67 |
| Revenue | ★ $30,713,000,000.00 | $2,378,193,000.00 |
| Revenue This Year | $14.46 | $38.63 |
| Revenue Next Year | $3.12 | $4.73 |
| P/E Ratio | $250.77 | ★ $81.00 |
| Revenue Growth | ★ 9.18 | 5.06 |
| 52 Week Low | $120.11 | $34.39 |
| 52 Week High | $189.96 | $56.50 |
Technical Indicators
Market Signals| Indicator | NRG | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.83 | 52.22 |
| Support Level | $127.11 | $35.33 |
| Resistance Level | $173.02 | $56.50 |
| Average True Range (ATR) | 4.92 | 1.30 |
| MACD | 0.65 | -0.28 |
| Stochastic Oscillator | 68.47 | 19.61 |
Price Performance
Historical ComparisonAbout NRG NRG Energy Inc.
NRG Energy is one of the largest retail energy providers in the US, with 6 million customers. Vivint Smart Home, which NRG acquired in 2023, has 2 million home-services customers. NRG also is one of the largest US independent power producers, with 26 gigawatts of coal, gas, and oil power generation capacity in Texas and the Eastern US. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.